D&D Pharmatech
KOSDAQTotal Valuation
D&D Pharmatech carries a market capitalization of 3.66T, placing it among publicly traded companies globally. Its enterprise value stands at 2.92T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.66T |
| Enterprise Value | 2.92T |
Share Statistics
D&D Pharmatech currently has 43.54M shares outstanding.
| Shares Outstanding | 43.54M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 974.32, and the price-to-book ratio stands at -9.16.
| PE Ratio | N/A |
| PS Ratio | 974.32 |
| PB Ratio | -9.16 |
| P/TBV Ratio | 68.48 |
| P/FCF Ratio | -118.07 |
| P/OCF Ratio | -117.90 |
Enterprise Valuation
| EV / Sales | 967.96 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
D&D Pharmatech maintains a current ratio of 8.02, meaning it holds 8.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.10, indicating elevated leverage, while an interest coverage ratio of -89.33 demonstrates limited ability to service its debt obligations.
| Current Ratio | 8.02 |
| Quick Ratio | 4.29 |
| Debt / Equity | 8.10 |
| Debt / EBITDA | -0.17 |
| Interest Coverage | -89.33 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -25.63 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | -1.35B |
| Effective Tax Rate | N/A |
Stock Price Statistics
D&D Pharmatech's stock has gained approximately 309.74421% over the past 52 weeks. The 50-day moving average sits at 75,120.00, while the 200-day moving average is 72,926.38.
| Beta (5Y) | N/A |
| 52-Week Price Change | 309.74421% |
| 50-Day Moving Average | 75,120.00 |
| 200-Day Moving Average | 72,926.38 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, D&D Pharmatech generated 3.01B in revenue and converted that into -23.20B in net income, yielding earnings per share of -554.53. EBITDA reached -35.80B, while operating income came in at -35.80B.
| Revenue | 3.01B |
| Gross Profit | 3.01B |
| Operating Income | -35.80B |
| Pretax Income | -25.36B |
| Net Income | -23.20B |
| EBITDA | -35.80B |
| EBIT | -35.80B |
| Earnings Per Share (EPS) | -554.53 |
Balance Sheet
D&D Pharmatech holds 24.57B in cash and equivalents against 5.99B in total debt, resulting in a net debt position of -24.57B. Total book value stands at -320.51B, with working capital of 40.17B providing operational flexibility.
| Cash & Cash Equivalents | 24.57B |
| Total Debt | 5.99B |
| Net Debt | -24.57B |
| Equity (Book Value) | -320.51B |
| Book Value Per Share | -7,402.55 |
| Working Capital | 40.17B |
Cash Flow
D&D Pharmatech produced -24.90B in operating cash flow over the past twelve months. After subtracting -36.59M in capital expenditures, free cash flow totaled -24.94B - equivalent to -575.91 per share.
| Operating Cash Flow | -24.90B |
| Capital Expenditures | -36.59M |
| Free Cash Flow | -24.94B |
| FCF Per Share | -575.91 |
Margins
D&D Pharmatech operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -1,188.29 and net profit margin of -770.03 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -1,188.29 |
| Pretax Margin | -841.82 |
| Profit Margin | -770.03 |
| EBITDA Margin | -1,188.29 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.81 |
| FCF Yield | -0.85 |
Stock Splits
D&D Pharmatech's most recent stock split took place on November 13, 2025 with a 1:4 split ratio.
| Last Split Date | 11/13/2025 |
| Split Ratio | 1:4 |
Scores
D&D Pharmatech posts an Altman Z-Score of 86.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 86.07 |